Official Journal of the Society

                 Nucleic Acid Therapeutics (formerly Oligonucleotides) is the official journal of the OTS.

          Your OTS membership includes a print and online subscription to the journal, a $366 value!

               Become a member of OTS today to start your subscription to Nucleic Acid Therapeutics!
                                           

Due to the explosion of scientific knowledge and the rapidly increasing number of manuscript submissions, Oligonucleotides has changed its title and broadened its scope under a new title Nucleic Acid Therapeutics.   Click here to see a table of contents and sign up for news alerts.

Editors Fintan Steele and C.A. Stein have added Mark Kay (Stanford University School of Medicine), Bruce A. Sullenger (Duke University), and Dieter Gruenert (University of California, San Francisco) to the Journal editorial leadership team, which includes European Editor Jens Kurreck and Asian Editor Dong-ki Lee. 

The expanded content includes: oligonucleotides; RNAi, siRNAs, shRNAs, and miRNAs; aptamers; RNA nanoparticles; gene modification with oligos; antisense applications; nucleoside and nucleotide analogs; peptide nucleic acids; ribozymes; DNA-modified gene therapy; DNAzymes; other nucleic acid modalities; and much more.

The Journal features rapid peer review and publication online within 6 weeks of acceptance. We welcome your manuscript submissions. Detailed information and instructions for authors is available online.

Online Journal Access

Within a few weeks of renewing your membership, you will receive an email notification for online access to the journal.  Once you have activated your online membership, you may access the journal by logging in here.

Should you need a temporary password until your subscription notification is emailed to you, please contact us.